Serum activin A and B, and follistatin in critically ill patients with influenza A(H1N1) infection

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Linko, Rita ^a   Hedger, Mark P ^b   Pettilä, Ville ^a   Ruokonen, Esko ^c   Ala Kokko, Tero ^d   Ludlow, Helen ^e   de Kretser, David M ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MONASH UNIVERSITY   (Australia)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e OXFORD BROOKES UNIVERSITY   (United Kingdom)

Author keywords

Activin A; Activin B; Acute respiratory distress syndrome; Follistatin; H1N1 influenza; Interleukin 6

Indexed keywords

ACTIVIN A; FOLLISTATIN; INTERLEUKIN 10; INTERLEUKIN 6; MYELOPID; ACTIVIN;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FINLAND; HOSPITAL ADMISSION; HUMAN; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; AGED; BLOOD; COMMUNICABLE DISEASE; COMPARATIVE STUDY; COMPLICATION; CRITICAL ILLNESS; INFLUENZA; INFLUENZA VIRUS A H1N1; MIDDLE AGED; VIROLOGY;

ACTIVINS; ADULT; AGED; COMMUNICABLE DISEASES; CRITICAL ILLNESS; FEMALE; FOLLISTATIN; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY;

EID: 84900540464     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-253     Document Type: Article

References (37)

1. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci U S A 2007, 104:16239-16244. 10.1073/pnas.0705971104, 2042191, 17911255.
2. Matsuse T, Ikegami A, Ohga E, Hosoi T, Oka T, Kida K, Fukayama M, Inoue S, Nagase T, Ouchi Y, Fukuchi Y. Expression of immunoreactive activin A protein in remodeling lesions associated with interstitial pulmonary fibrosis. Am J Pathol 1996, 148:707-713. 1861725, 8774126.
3. Hübner G, Hu Q, Smola H, Werner S. Strong induction of activin expression after injury suggests an important role of activin in wound repair. Dev Biol 1996, 173:490-498. 10.1006/dbio.1996.0042, 8606007.
4. Jones KL, de Kretser DM, Clarke IJ, Scheerlinck J-PY, Phillips DJ. Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe. J Endocrinol 2004, 182:69-80. 10.1677/joe.0.1820069, 15225132.
5. Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ. Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 2000, 141:1905-1908. 10.1210/endo.141.5.7531, 10803603.
6. Robson NC, Wei H, McAlpine T, Kirkpatrick N, Cebon J, Maraskovsky E. Activin-A attenuates several human natural killer cell functions. Blood 2009, 113:3218-3225. 10.1182/blood-2008-07-166926, 19141859.
7. Michel U, Ebert S, Phillips D, Nau R. Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia. Eur J Endocrinol 2003, 148:559-564. 10.1530/eje.0.1480559, 12720540.
8. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000, 342:1334-1349. 10.1056/NEJM200005043421806, 10793167.
9. Apostolou E, Stavropoulos A, Sountoulidis A, Xirakia C, Giaglis S, Protopapadakis E, Ritis K, Mentzelopoulos S, Pasternack A, Foster M, Ritvos O, Tzelepis GE, Andreakos E, Sideras P. Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. Am J Respir Crit Care Med 2012, 185:382-391. 10.1164/rccm.201105-0784OC, 22161160.
10. Aoki F, Kurabayashi M, Hasegawa Y, Kojima I. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am J Respir Crit Care Med 2005, 172:713-720. 10.1164/rccm.200412-1620OC, 15976370.
11. Influenza Investigators ANZIC, Webb SAR, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361:1925-1934.
12. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouret P, Khwala K, MCIntyre L, Menon K, Hutchinson J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302:1872-1879. 10.1001/jama.2009.1496, 19822627.
13. Meade MO, Guyatt GH, Cook RJ, Groll R, Kachura JR, Wigg M, Cook DJ, Slutsky AS, Stewart TE. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163:490-493. 10.1164/ajrccm.163.2.2006067, 11179128.
14. Bermejo-Martin JF, de Lejarazu Ortiz R, Pumarola T, Rello J, Almansa R, Ramírez P, Martin-Loeches I, Varillas D, Gallegos MC, Serón C, Micheloud D, Gomez JM, Tenorio-Abreu A, Ramos MJ, Molina ML, Huidobro S, Sanchez E, Gordon M, Fernandez V, Del Castillo A, Marcos MA, Villanueve B, Lopez CJ, Rodriguez-Dominguez M, Galan JC, Canton R, Lietor A, Rojo S, Eisos JM, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Critical care (London, England) 2009, 13:R201.
15. To KKW, Hung IFN, Li IWS, Lee K-L, Koo C-K, Yan W-W, Liu R, Ho K-Y, Chu K-H, Watt C-L, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JF, Wong SS, Zheng B, Chen H, Lau CC, Tse H, Cheng VC, Chan KH, Yuen KY. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010, 50:850-859. 10.1086/650581, 20136415.
16. Mauad T, Hajjar L, Callegari G, da Silva L, Schout D, Galas F, Alves V, Malheiros D, Auler J, Ferreira A, Borsato MR, Bezerra SM, Gutierrez PS, Caldini ET, Pasqualucci CA, Dolhnikoff M, Saldiva PH. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010, 181:72-79. 10.1164/rccm.200909-1420OC, 19875682.
17. Lee N, Wong CK, Chan PKS, Chan MCW, Wong RYK, Lun SWM, Ngai KLK, Lui GCY, Wong BCK, Lee SK, Choi KW, Hui DS. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One 2011, 6:e26050. 10.1371/journal.pone.0026050, 3192778, 22022504.
18. Chiaretti A, Pulitanò S, Barone G, Ferrara P, Romano V, Capozzi D, Riccardi R. IL-1β and IL-6 upregulation in children with H1N1 influenza virus infection. Mediators Inflamm 2013, 2013:1-8.
19. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995, 107:1062-1073. 10.1378/chest.107.4.1062, 7705118.
20. Linko R, Pettilä V, Ruokonen E, Varpula T, Karlsson S, Tenhunen J, Reinikainen M, Saarinen K, Perttilä J, Parviainen I, Ala-Kokko T, . FINNH1N1-STUDY GROUP Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand 2011, 55:971-979. FINNH1N1-STUDY GROUP.
21. Bernard GR, Artigas A, Carlet J, Falke K, Hudson L, Lamy M, Spragg R. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824. 10.1164/ajrccm.149.3.7509706, 7509706.
22. Knight PG, Muttukrishna S, Groome NP. Development and application of a two-site enzyme immunoassay for the determination of " total" activin-A concentrations in serum and follicular fluid. J Endocrinol 1996, 148:267-279. 10.1677/joe.0.1480267, 8699141.
23. Ludlow H, Phillips DJ, Myers M, McLachlan RI, de Kretser DM, Allan CA, Anderson RA, Groome NP, Hyvönen M, Duncan WC, Muttukrishna S. A new " total" activin B enzyme-linked immunosorbent assay (ELISA): development and validation for human samples. Clin Endocrinol 2009, 71:867-873.
24. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod 1999, 14:827-832. 10.1093/humrep/14.3.827, 10221721.
25. Brown CW, Li L, Houston-Hawkins DE, Matzuk MM. Activins are critical modulators of growth and survival. Mol Endocrinol 2003, 17:2404-2417. 10.1210/me.2003-0051, 14551263.
26. Wu H, Chen Y, Winnall WR, Phillips DJ, Hedger MP. Acute regulation of activin A and its binding protein, follistatin, in serum and tissues following lipopolysaccharide treatment of adult male mice. Am J Physiol Regul Integr Comp Physiol 2012, 303:R665-R675. 10.1152/ajpregu.00478.2011, 22855279.
27. Chen Y, Wu H, Winnall WR, Loveland KL, Makanji Y, Phillips DJ, Smith JA, Hedger MP. Tumour necrosis factor-α stimulates human neutrophils to release preformed activin A. Immunol Cell Biol 2011, 89:889-896. 10.1038/icb.2011.12, 21445090.
28. Linko R, Okkonen M, Pettilä V, Perttilä J, Parviainen I, Ruokonen E, Tenhunen J, Ala-Kokko T, Varpula T, . FINNALI-study group Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive Care Med 2009, 35:1352-1361. 10.1007/s00134-009-1519-z, 19526218, FINNALI-study group.
29. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007, 131:954-963. 10.1378/chest.06-2100, 17426195.
30. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 2003, 36:290-294. 10.1002/ppul.10320, 12950040.
31. Yu J, Shao LE, Frigon NL, Lofgren J, Schwall R. Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Immunology 1996, 88:368-374. 10.1046/j.1365-2567.1996.d01-675.x, 1456346, 8774352.
32. Shao LE, Frigon NL, Yu A, Palyash J, Yu J. Contrasting effects of inflammatory cytokines and glucocorticoids on the production of activin A in human marrow stromal cells and their implications. Cytokine 1998, 10:227-235. 10.1006/cyto.1997.0282, 9576069.
33. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999, 282:54-61. 10.1001/jama.282.1.54, 10404912.
34. Papazian L, Gainnier M, Marin V, Donati S, Arnal J-M, Demory D, Roch A, Forel J-M, Bongrand P, Brégeon F, Sainty J-M. Comparison of prone positioning and high-frequency oscillatory ventilation in patients with acute respiratory distress syndrome. Crit Care Med 2005, 33:2162-2171. 10.1097/01.CCM.0000181298.05474.2B, 16215365.
35. Forel J-M, Roch A, Michelet P, Perrin G, Gainnier M, Papazian L. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006, 34:2749-2757. 10.1097/01.CCM.0000239435.87433.0D, 16932229.
36. de Kretser DM, Bensley JG, Pettila V, Linko R, Hedger MP, Hayward S, Allan CA, McLachlan RI, Ludlow H, Phillips DJ. Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Crit Care 2013, 17:R263. 10.1186/cc13093, 24172607.
37. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm 2011, 85:255-297.